Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $241.60, giving the company a market capitalization of 578.3B. It carries a P/E multiple of 21.32 and pays a dividend yield of 2.2%.
During the trading session on 2026-03-25, Johnson & Johnson(JNJ) shares reached a daily high of $241.60 and a low of $235.60. At a current price of $241.60, the stock is +2.5% higher than the low and still 0.0% under the high.
Trading volume for Johnson & Johnson(JNJ) stock has reached 6.44M, versus its average volume of 8.38M.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
JNJ News
VIG Returned 223% Over 10 Years and Still Costs Almost Nothing By John Seetoo Published Mar 25, 1:30PM EDT Quick Read Vanguard Dividend Appreciation ETF (VIG)...
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has issued an update. KYORIN Pharmaceutical has signed an exclusive distribution and promotion agreement in Japan...
With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize By John Seetoo Published Mar 24, 10:07AM EDT Quick Read iShares U.S. Pharm...
Analyst ratings
59%
of 29 ratingsMore JNJ News
Johnson & Johnson (NYSE:JNJ) has entered a Phase 1b combination clinical trial for metastatic castration resistant prostate cancer using its bispecific T cell e...
The great thing about dividends is they'll land in your pocket every year no matter what the market or even the particular stock is doing. So you can count on a...
Shares of AbbVie ABBV fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe p...
Barclays raised the firm’s price target on Johnson & Johnson to $234 from $217 and keeps an Equal Weight rating on the shares. The firm says its analysis confir...
On 18 March 2026, Johnson & Johnson received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor antagonist for moderate-to-seve...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.